Cancers

Journal Browser

► Journal Browser

Gastric Cancer Surgery: Gastrectomy, Risk, and Related Prognosis

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 October 2024 | Viewed by 1028

Share This Special Issue

Special Issue Information

Dear Colleagues,

Gastric cancer (GC) is one of the most frequent reasons for cancer-related deaths worldwide. Multimodal therapeutic strategies are now pragmatically tailored to each patient, and surgical treatment is combined with perioperative (West) or adjuvant (East) chemotherapy in locally advanced disease. A radical but safe gastrectomy remains the cornerstone of GC treatment. Moreover, quality-of-life (QoL) outcome measures are now routinely utilized in order to select the optimal type of gastrectomy, as well as reconstruction method.

The debate continues on a standard of surgical treatment for patients with proximal GC or at the esophago-gastric junction. While (transhiatal-extended) total gastrectomy (TG) significantly impairs the long-term QoL of patients, proximal gastrectomy (PG) offers similar survival rates and a reduced morbidity with an improved QoL compared to TG, provided an anti-reflux procedure is used.

Traditionally, gastrectomy was performed as an open procedure, although minimally invasive surgical (MIS) approaches have undergone widespread adoption, including laparoscopic and robotic-assisted gastrectomy. The improved recovery outcomes associated with the MIS approaches support their use for patients with resectable GC.

Recently, the prognosis of patients with primary unresectable, incurable, and oligo-metastatic GC has changed through the targeted and immuno-therapy of patients whose tumours express relevant predictive biomarkers. Whether this conversion (immuno-)therapy would influence the extent of gastrectomy and lymph node dissection is unknown.

Prof. Dr. Wojciech Piotr Polkowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

gastric cancer
surgical treatment
gastrectomy
outcome
minimally invasive surgical

Published Papers (1 paper)

Research

14 pages, 2284 KiB

Open AccessArticle

Prognostic Value of Inflammatory Burden Index in Advanced Gastric Cancer Patients Undergoing Multimodal Treatment

by Zuzanna Pelc, Katarzyna Sędłak, Radosław Mlak, Magdalena Leśniewska, Katarzyna Mielniczek, Piotr Rola, Jacek Januszewski, Olena Zhaldak, Anna Rekowska, Katarzyna Gęca, Magdalena Skórzewska, Wojciech P. Polkowski, Timothy M. Pawlik and Karol Rawicz-Pruszyński

Cancers 2024, 16(4), 828; https://doi.org/10.3390/cancers16040828 - 18 Feb 2024

Viewed by 822

Abstract

Since increasing evidence underlines the prominent role of systemic inflammation in carcinogenesis, the inflammation burden index (IBI) has emerged as a promising biomarker to estimate survival outcomes among cancer patients. The IBI has only been validated in Eastern gastric cancer (GC) patients; therefore, the aim of this study was to evaluate the IBI as a prognostic biomarker in Central European GC patients undergoing multimodal treatment. Ninety-three patients with histologically confirmed GC who underwent multimodal treatment between 2013 and 2021 were included. Patient recruitment started with the standardization of neoadjuvant chemotherapy (NAC). Blood samples were obtained one day prior to surgical treatment. The textbook outcome (TO) served as the measure of surgical quality, and tumor responses to NAC were evaluated according to Becker’s system tumor regression grade (TRG). A high IBI was associated with an increased risk of postoperative complications (OR 2.95, 95% CI 1.13–7.72). In multivariate analysis, a high IBI (HR = 2.56, 95% CI 1.28–5.13) and a high neutrophil-to-lymphocyte ratio (NLR, HR = 2.55, 95% CI 1.32–4.94) were associated with an increased risk of death, while NAC administration (HR = 0.40, 95% CI 0.18–0.90) and TO achievement (HR = 0.42, 95% CI 0.22–0.81) were associated with a lower risk of death. The IBI was associated with postoperative complications and mortality among GC patients undergoing multimodal treatment. Full article

(This article belongs to the Special Issue Gastric Cancer Surgery: Gastrectomy, Risk, and Related Prognosis)

► Show Figures